Lista de obras -

A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients

artículo científico publicado en 2011

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

artículo científico publicado en 2004

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts

artículo científico publicado en 2003

Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?

artículo científico publicado en 2019

Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature

artículo científico publicado en 2003

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

artículo científico publicado en 2019

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

artículo científico publicado en 2004

ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical Trial

artículo científico publicado en 2020

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection

artículo científico publicado en 2022

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

artículo científico publicado en 2004

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

artículo científico publicado en 2004

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

artículo científico publicado en 2004

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

artículo científico publicado en 2005

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study

artículo científico publicado en 2007

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

artículo científico publicado en 2008

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

scientific article published on 01 February 2014

Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?

scientific article published on 19 March 2020

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

artículo científico publicado en 2005

Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients

artículo científico publicado en 2020

Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation. ⬇️

artículo científico publicado en 2014

Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

artículo científico publicado en 2003

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission

artículo científico publicado en 2004

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients

artículo científico publicado en 2004

Lista de obras de

A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts

Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?

Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical Trial

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients

Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients

Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation. ⬇️

Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients